Standard of Care sensibility: Cisplatin = no (2mg/kg)
BICR 18 cells
Human BICR 18 cells were isolated from the lymph node of a patient with metastatic larynx H&N squamous cells carcinoma.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing BICR 18 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1:(View PDF)
Tumour growth curve of the BICR 18 cells as xenograft Mean ± SEM (n=3; take rate 100%)
Standard-Of-Care Drug Responses
cislaplatin 2 mg/kg qw → No response
Figure 2: (View PDF)
Effect of cisplatin treatment on BICR 18 tumour growth Mean ± SEM (n=5 per group; take rate 100%)